VEGF-A Concentrations in Supernatants of HUT 78 Cells Under Different Conditions of Stimulation
| Stimuli . | VEGF-A (ng/mL) . | ||
|---|---|---|---|
| Day 1 . | Day 3 . | Day 5 . | |
| TCM (25%)* | 3.1 ± 0.3 | 16.4 ± 1.5 | 28.7 ± 0.9 |
| HIV-TCM (25%)* | 5.8 ± 0.7 | 32.2 ± 3.4 | 53.4 ± 2.1 |
| TPA-TCM (25%)* | 8.5 ± 1.6 | 47.6 ± 1.2 | 65.6 ± 0.6 |
| TNFα (250 pg/mL) | 2.1 ± 0.1 | 21.5 ± 0.3 | 52.7 ± 2.6 |
| IFNγ (1 U/mL) | 2.1 ± 0.1 | 16.0 ± 0.4 | 45.0 ± 0.6 |
| IL-1β (875 pg/mL) | 2.3 ± 0.1 | 18.3 ± 0.1 | 51.3 ± 2.0 |
| IL-6 (200 U/mL) | 2.1 ± 0.2 | 20.2 ± 0.9 | 38.7 ± 0.2 |
| SH-TCM | 8.3 ± 1.2 | 54.3 ± 0.8 | 84.1 ± 2.4 |
| Stimuli . | VEGF-A (ng/mL) . | ||
|---|---|---|---|
| Day 1 . | Day 3 . | Day 5 . | |
| TCM (25%)* | 3.1 ± 0.3 | 16.4 ± 1.5 | 28.7 ± 0.9 |
| HIV-TCM (25%)* | 5.8 ± 0.7 | 32.2 ± 3.4 | 53.4 ± 2.1 |
| TPA-TCM (25%)* | 8.5 ± 1.6 | 47.6 ± 1.2 | 65.6 ± 0.6 |
| TNFα (250 pg/mL) | 2.1 ± 0.1 | 21.5 ± 0.3 | 52.7 ± 2.6 |
| IFNγ (1 U/mL) | 2.1 ± 0.1 | 16.0 ± 0.4 | 45.0 ± 0.6 |
| IL-1β (875 pg/mL) | 2.3 ± 0.1 | 18.3 ± 0.1 | 51.3 ± 2.0 |
| IL-6 (200 U/mL) | 2.1 ± 0.2 | 20.2 ± 0.9 | 38.7 ± 0.2 |
| SH-TCM | 8.3 ± 1.2 | 54.3 ± 0.8 | 84.1 ± 2.4 |
HUT 78 (1 × 106) cells were incubated for 1, 3, and 5 days with 25% of CM obtained from uninfected (TCM), HIV-1–infected (HIV-TCM), or TPA-treated (TPA-TCM) HUT 78 cells or with single cytokines or the combination of all the different cytokines in the respective concentrations (SH-TCM). VEGF-A concentrations were determined in duplicate by ELISA. The mean values and standard deviations of two independent experiments are shown.
Corrected VEGF-A concentrations are presented. The concentration of VEGF-A present in TCM, HIV-TCM, and TPA-TCM used for induction in the respective experiments has been subtracted.